#United States #New York #The Gross Law Firm #Cassava Sciences #SAVA

Urgent Notice to Shareholders of Cassava Sciences, Inc.

Cassava Sciences, Inc. (NASDAQ: SAVA) shareholders are being urged to take action as critical deadlines approach. The Gross Law Firm has recently issued a notification directed at investors who purchased shares during a specific class period. This notice serves as a reminder for these shareholders to discuss their rights before the looming deadline of February 10, 2025.

Class Period and Allegations Against Cassava

The designated class period spans from February 7, 2024, to November 24, 2024. During this timeframe, shareholders may have been impacted by the misleading information regarding Cassava's primary drug candidate, simufilam. Allegations suggest that the company's executives provided overly optimistic statements about simufilam's efficacy in treating Alzheimer's Disease, which ultimately misled investors.

On November 25, 2024, the company published disappointing results from its ongoing Phase 3 clinical trials, specifically the study named ReThink-ALZ. The results indicated that simufilam did not perform better than a placebo across all specified endpoints. This shocking revelation led to a swift and dramatic decline in Cassava's stock price, plummeting approximately 83.76% in a single day—from a closing price of $26.48 on November 22, 2024, to just $4.30 per share.

Why Reach Out to The Gross Law Firm?

The Gross Law Firm is committed to protecting the rights of investors and offers a platform for affected shareholders to discuss the possibility of being appointed as lead plaintiffs in this case. Notably, this appointment is not mandatory for participating in potential recovery efforts. Shareholders are encouraged to register their information as soon as possible to ensure they are updated throughout the case's progression.

If you purchased shares during the aforementioned time frame, it’s vital not to delay in registering with The Gross Law Firm. Participation in this legal action entails no financial obligation for the shareholders, meaning that engagement is entirely free of charge.

Steps to Take

Affected parties are invited to follow specific procedures to safeguard their interests:
1. Contact The Gross Law Firm: Begin by reaching out to the firm through the links provided in their notification. This includes filling out a loss submission form that outlines the details of your investment in Cassava Sciences, Inc. Submit your information here.

2. Register for Case Monitoring: Upon registration, investors will gain access to a portfolio monitoring service that delivers updates on the case's status throughout its lifecycle.

3. Final Deadline: Keep in mind the February 10, 2025 deadline to be considered for lead plaintiff status.

The Role of The Gross Law Firm

The Gross Law Firm is recognized nationally for its expertise in class action lawsuits, particularly those involving investor rights against fraudulent corporate actions. The firm emphasizes the importance of transparency in corporate communication and strives to hold companies like Cassava Sciences accountable for any misleading or fraudulent practices that can lead to significant losses for their shareholders.

In conclusion, if you're a shareholder of Cassava Sciences, it’s crucial to act swiftly and connect with The Gross Law Firm to discuss your rights and potential next steps. This timely response could potentially protect your interests and facilitate compensation for any losses incurred as a result of the alleged misrepresentation by Cassava's management team.